HARVARD BIOSCIENCE INC — Director's Dealing 2019

Jul 1, 2019

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: HARVARD BIOSCIENCE INC (HBIO)
CIK: 0001123494
Period of Report: 2019-06-28

Reporting Person: Duchemin Jeffrey (Director, Chief Executive Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2019-06-28	Common Stock	J	3334	$1.70	Acquired	750001	Direct

Footnotes

F1: Represents shares acquired under the Issuer's Employee Stock Purchase Plan.

F2: Represents the purchase price for each share purchased under the Employee Stock Purchase Plan and equals 85% of the fair market value of common stock on June 28, 2019, being the exercise date under the plan.

F3: Includes (a) a deferred stock award of 56,517 restricted stock units with performance based vesting conditions, which shall vest in three equal installments on March 7, 2020, 2021 and 2022, contingent upon achievement of a performance condition tied to relative total shareholder return; (b) a deferred stock award of 113,034 restricted stock units which shall vest in four equal installments on January 1, 2020, 2021, 2022 and 2023; (c) a deferred stock award of 70,833 restricted stock units which vest in equal installments on January 1, 2020, 2021 and 2022; (d) a deferred stock award of 178,804 restricted stock units which shall vest in equal installments on January 1, 2020 and 2021; (e) a deferred stock award of 72,916 restricted stock units which shall vest on January 1, 2020;

F4: continuation of footnote 3 above: (f) a deferred stock award of 7,556 restricted stock units, which vest in equal installments on May 24, 2020 and May 24, 2021; and (g) 250,341 shares of common stock held by the Reporting Person.